Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway
10.1038/sj.leu.2404960
Saved in:
Main Authors: | Zhou, J., Pan, M., Xie, Z., Loh, S.-L., Bi, C., Tai, Y.-C., Lilly, M., Lim, Y.-P., Han, J.-H., Glaser, K.B., Albert, D.H., Davidsen, S.K., Chen, C.-S. |
---|---|
Other Authors: | NATIONAL UNIVERSITY MEDICAL INSTITUTES |
Format: | Article |
Published: |
2014
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/108562 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside
by: Zhou, J., et al.
Published: (2011) -
In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor
by: Zhou, J., et al.
Published: (2011) -
In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor
by: Zhou, J., et al.
Published: (2011) -
In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor
by: Zhou, J., et al.
Published: (2011) -
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
by: Jasinghe, V.J., et al.
Published: (2011)